Journal
ANNALS OF CLINICAL BIOCHEMISTRY
Volume 45, Issue -, Pages 93-95Publisher
ROYAL SOC MEDICINE PRESS LTD
DOI: 10.1258/acb.2007.007068
Keywords
-
Categories
Funding
- Biotechnology and Biological Sciences Research Council [B/E52708X/1] Funding Source: Medline
- Medical Research Council Funding Source: Medline
- Wellcome Trust Funding Source: Medline
- Department of Health [DHCS/05/05] Funding Source: Medline
- National Institute for Health Research [DHCS/05/05, NF-SI-0507-10337] Funding Source: researchfish
Ask authors/readers for more resources
Background: Peptide YY (PYY3-36) infused to levels within the physiological range reduces appetite and food intake in humans without nausea. However, PYY3-36, has previously been shown to cause nausea at higher doses. Methods: We studied the relationship of PYY3-36, nausea and food intake in six volunteers, using three different PYY3-36 preparations infused to achieve supraphysiological PYY plasma levels. Results: Supraphysiological levels of PYY caused nausea in five subjects (P < 0.05). Although PYY3-36 increased satiety (P < 0.05) and reduced food intake (P < 0.05), no greater enhancement of satiety or inhibition of food intake was observed compared with previous reports. Conclusions: This study cautions against the use of supraphysiological doses of PYY3-36 as it may increase nausea with no benefit in food reduction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available